As biotech innovations continue to merge with the world of cryptocurrency, Propanc Biopharma, an Australia-based company focusing on cancer treatments, has taken a bold step. This move involves partnering with Hexstone Capital, a family office specializing in digital assets, to establish a dedicated crypto treasury to accelerate its research and development efforts. With this investment of up to $100 million, the biotech firm aims to take its lead treatment for cancer, PRP, into human trials by 2026. The company’s cryptocurrency strategy reflects a growing trend among bio tech firms seeking to utilize digital assets for financial security and research funding. .